# Xintong Pharmacy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xintong-pharmacy

- Industry: Pharmaceuticals
- Headquarters: Xi'an, China
- Website: www.xtyw.com.cn
- Total disclosed funding: $27M
- Latest round: Series B (Dec 1, 2017)
- Investors on record: 2

## About

Established in 2000 and based in Xi'an, China, Xintong Pharmacy operates as a pharmaceutical company dedicated to providing traditional Chinese medicine and chemical drugs. It acquired Innovative Enterprises in Xi'an City Certificate. In September 2020, the company raised more than CNY 100 million in pre-IPO funding.

The company mainly provides drugs focusing on chronic hepatitis B, liver cancer, epilepsy and other diseases. It has nine projects in development, of which CE-phosphophenytoin sodium injection, which is used for the treatment of generalized tonic-clonic status epilepticus, has been submitted for marketing authorization. Paradefovir Mesylate Tablets, a targeted drug for the treatment of chronic hepatitis B, is in Phase III clinical trials. MB07133 for injection alone for the treatment of advanced primary liver cancer is in Phase II clinical trials. Hepunofovir fumarate tablets, a potential long-acting inhibitor for the treatment of chronic hepatitis B, is in Phase I clinical trials. Xintong Pharmacy also provides generic drugs and traditional Chinese medicine.

## Funding rounds

- Series B, Dec 1, 2017, $27M — Hanfor Capital, Taizhou Yutong Medical Technology

## Investors

- Hanfor Capital (https://capitalatlas.ai/funds/hanfor-capital) — Series B
- Taizhou Yutong Medical Technology — Series B